First Turn Management LLC Invests $21.49 Million in Viridian Therapeutics, Inc. $VRDN

First Turn Management LLC acquired a new stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 690,528 shares of the company’s stock, valued at approximately $21,489,000. Viridian Therapeutics comprises approximately 2.5% of First Turn Management LLC’s holdings, making the stock its 19th biggest holding. First Turn Management LLC owned about 0.72% of Viridian Therapeutics as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in VRDN. Aster Capital Management DIFC Ltd purchased a new stake in shares of Viridian Therapeutics during the third quarter valued at $35,000. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Viridian Therapeutics during the fourth quarter valued at $36,000. Bessemer Group Inc. grew its holdings in shares of Viridian Therapeutics by 947.7% during the third quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock valued at $45,000 after buying an additional 1,886 shares during the last quarter. Larson Financial Group LLC purchased a new stake in shares of Viridian Therapeutics during the third quarter valued at $52,000. Finally, US Bancorp DE grew its holdings in shares of Viridian Therapeutics by 23.2% during the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock valued at $53,000 after buying an additional 463 shares during the last quarter.

Insider Buying and Selling

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc purchased 1,176,470 shares of the stock in a transaction on Monday, May 11th. The shares were bought at an average cost of $17.00 per share, with a total value of $19,999,990.00. Following the completion of the acquisition, the director owned 5,090,928 shares in the company, valued at $86,545,776. This trade represents a 30.05% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 2.40% of the company’s stock.

Viridian Therapeutics Price Performance

NASDAQ:VRDN opened at $16.35 on Friday. Viridian Therapeutics, Inc. has a one year low of $13.18 and a one year high of $34.29. The company has a debt-to-equity ratio of 0.10, a quick ratio of 15.15 and a current ratio of 15.15. The firm has a market cap of $1.69 billion, a price-to-earnings ratio of -4.92 and a beta of 0.90. The firm’s fifty day moving average is $15.96 and its two-hundred day moving average is $25.29.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.16. Viridian Therapeutics had a negative net margin of 490.31% and a negative return on equity of 80.19%. The company had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.04 million. During the same period in the prior year, the company earned ($0.87) earnings per share. The firm’s revenue was up 95.8% on a year-over-year basis. Research analysts expect that Viridian Therapeutics, Inc. will post -3.87 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Evercore set a $26.00 price objective on shares of Viridian Therapeutics in a report on Friday, May 15th. HC Wainwright dropped their price objective on shares of Viridian Therapeutics from $34.00 to $22.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Stifel Nicolaus set a $39.00 price objective on shares of Viridian Therapeutics in a report on Wednesday, May 13th. Wells Fargo & Company dropped their price objective on shares of Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating on the stock in a report on Tuesday, March 31st. Finally, Wall Street Zen raised shares of Viridian Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday. Twelve equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $36.14.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.